Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Indication assessment · §3

Obesity in children and adolescents — trial records

Trial records in the Institute's register bearing on obesity in children and adolescents.

Document identifier
CEI-IN-09/3
Series
Indication assessment
Version
2.3
Published
31 Oct 2025
Last reviewed
31 Oct 2025
Next review
31 Oct 2027
Identifier
10.71829/cei.ind.9
Certainty
Not rated
Cycle
2025 Q4
ICD-11
5B81
Category
Metabolic

§3Trials in this indication

10 trial records in the Institute's register bear on this indication, of which 2 are published trials.

Table 2. Trial records bearing on obesity in children and adolescents.

RecordCompoundPhaseDesignRandomisedYear
STEP-TEENSSemaglutidePhase 3Randomised, double-blind, placebo-controlled2012022
SCALE-TEENSLiraglutidePhase 3Randomised, double-blind, placebo-controlled2512020
STEP-TEENS-HEPATIC-IMPprogramme recordSemaglutidePhase 1Phase 1 ascending dose2022
SCALE-TEENS-PKprogramme recordLiraglutidePhase 1Phase 1 ascending dose2020
STEP-TEENS-DDIprogramme recordSemaglutidePhase 1Randomised crossover2022
SCALE-TEENS-RENAL-IMPprogramme recordLiraglutidePhase 1Phase 1 ascending dose2020
STEP-TEENS-PKprogramme recordSemaglutidePhase 1Phase 1 ascending dose2022
SCALE-TEENS-HEPATIC-IMPprogramme recordLiraglutidePhase 1Phase 1 ascending dose2020
SCALE-TEENS-DDIprogramme recordLiraglutidePhase 1Randomised crossover2020
SCALE-TEENS-BODY-COMPprogramme recordLiraglutidePhase 3Randomised, double-blind, placebo-controlled2020
This facet in the trial register.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine 2015;373(1):11–22. doi:10.1056/NEJMoa1411892 · PMID 26132939

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.